Prevention of Chronic Kidney Disease and Subsequent Effect on Mortality: A Systematic Review and Meta-Analysis

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Khan, Usman A ^a   Garg, Amit X ^b   Parikh, Chirag R ^a   Coca, Steven G ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANGIOTENSIN RECEPTOR ANTAGONIST; BARDOXOLONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBOPAMINE; PLACEBO; VITAMIN B GROUP;

ADULT; ADVERSE OUTCOME; ALBUMINURIA; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; DIET THERAPY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

DISEASE PROGRESSION; HUMANS; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; RISK;

EID: 84883239242     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071784     Document Type: Review

References (85)

1. CDC (2007) Prevalence of chronic kidney disease and associated risk factors-United States, 1999-2004. MMWR Morb Mortal Wkly Rep 56: 161-165.
2. Zhang QL, Rothenbacher D, (2008) Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 8: 117.
3. NKF (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39: S1-266.
4. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY, (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305.
5. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, et al. (2001) Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 12: 218-225.
6. Foley RN, Parfrey PS, Sarnak MJ, (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32: S112-119.
7. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, et al. (1998) Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 32: 853-906.
8. Levin A, Singer J, Thompson CR, Ross H, Lewis M, (1996) Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 27: 347-354.
9. Sarnak MJ, Levey AS, (2003) Schoolwerth AC, Coresh J, Culleton B, et al (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 42: 1050-1065.
10. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, et al. (2006) Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 17: 2034-2047.
11. Garg AX, Meirambayeva A, Huang A, Kim J, Prasad GV, et al. (2012) Cardiovascular disease in kidney donors: matched cohort study. BMJ 344: e1203.
12. Wald R, Quinn RR, Luo J, Li P, Scales DC, et al. (2009) Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. JAMA 302: 1179-1185.
13. Higgins JP, Altman D, Sterne JA (2011) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT GS, editor. Cochrane Handbook for Systematic Reviews of Interventions version 510.
14. van Houwelingen HC, Arends LR, Stijnen T, (2002) Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 21: 589-624.
15. Zeger SL, Liang KY, Albert PS, (1988) Models for longitudinal data: a generalized estimating equation approach. Biometrics 44: 1049-1060.
16. DCCT (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329: 977-986.
17. MCSG (1996) Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. The Microalbuminuria Captopril Study Group. Diabetologia 39: 587-593.
18. GISEN (1997) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 349: 1857-1863.
19. UKPDS34 (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352: 854-865.
20. UKPDS33 (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352: 837-853.
21. HOPE (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.[Erratum appears in Lancet 2000 Sep 2; 356(9232): 860]. Lancet 355: 253-259.
22. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, et al. (2001) Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 285: 2719-2728.
23. Akizawa T, Asano Y, Morita S, Wakita T, Onishi Y, et al. (2009) Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial.[Erratum appears in Am J Kidney Dis. 2010 Mar; 55(3): 616]. Am J Kidney Dis 54: 459-467.
24. Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, et al. (2009) Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. Circulation 120: 1577-1584.
25. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, et al. (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. The Lancet 377: 2181-2192.
26. Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, et al. (2010) Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. The Lancet 375: 1173-1181.
27. Bakris GL, Toto RD, McCullough PA, Rocha R, Purkayastha D, et al. (2008) Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney International 73: 1303-1309.
28. Barnett AH, (2005) Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study. Acta Diabetologica 42Suppl 1: S42-49.
29. Bilous R, Chaturvedi N, Sjolie AK, Fuller J, Klein R, et al. (2009) Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Annals of Internal Medicine 151: 11-20, W13-14.
30. Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, et al. (2004) Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. American Journal of Nephrology 24: 32-40.
31. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, et al. (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New England Journal of Medicine 345: 861-869.
32. Chan JC, So WY, Yeung CY, Ko GT, Lau IT, et al. (2009) Effects of structured versus usual care on renal endpoint in type 2 diabetes: the SURE study: a randomized multicenter translational study. Diabetes Care 32: 977-982.
33. Dalla Vestra M, Pozza G, Mosca A, Grazioli V, Lapolla A, et al. (2004) Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes, Nutrition & Metabolism- Clinical & Experimental 17: 259-266.
34. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, et al. (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360: 129-139.
35. Facchini FS, Saylor KL, (2003) A low-iron-available, polyphenol-enriched, carbohydrate-restricted diet to slow progression of diabetic nephropathy. Diabetes 52: 1204-1209.
36. Fan FH, Xie D, Zhang X, Ping YC, Wei RZ, et al. (2007) Renoprotection of Optimal Antiproteinuric Doses (ROAD) study: A randomized controlled study of benazepril and losartan in chronic renal insufficiency. Journal of the American Society of Nephrology 18: 1889-1898.
37. Fogari R, Preti P, Zoppi A, Rinaldi A, Corradi L, et al. (2002) Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. American Journal of Hypertension 15: 1042-1049.
38. Gaede P, Vedel P, Parving HH, Pedersen O, (1999) Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 353: 617-622.
39. Goicoechea M, De Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, et al. (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clinical Journal of the American Society of Nephrology 5: 1388-1393.
40. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, et al. (2011) Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. New England Journal of Medicine 364: 907-917.
41. Hannedouche T, Landais P, Goldfarb B, el Esper N, Fournier A, et al. (1994) Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ 309: 833-837.
42. Heerspink HJL, Ninomiya T, Perkovic V, Woodward M, Zoungas S, et al. (2010) Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. European Heart Journal 31: 2888-2896.
43. House AA, Eliasziw M, Cattran DC, Churchill DN, Oliver MJ, et al. (2010) Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA 303: 1603-1609.
44. Huskey J, Lindenfeld J, Cook T, Targher G, Kendrick J, et al. (2009) Effect of simvastatin on kidney function loss in patients with coronary heart disease. Findings from the Scandinavian Simvastatin Survival Study (4S). Atherosclerosis 205: 202-206.
45. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, et al. (2010) Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.[Erratum appears in Lancet. 2010 Oct 30; 376(9751): 1466]. Lancet 376: 419-430.
46. Kendrick J, Shlipak MG, Targher G, Cook T, Lindenfeld J, et al. (2010) Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. American Journal of Kidney Diseases 55: 42-49.
47. Laffel LM, McGill JB, Gans DJ, (1995) The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. American Journal of Medicine 99: 497-504.
48. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: 1456-1462.
49. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, et al. (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine 345: 851-860.
50. Mann JFE, Schmieder RE, Dyal L, McQueen MJ, Schumacher H, et al. (2009) Effect of telmisartan on renal outcomes: a randomized trial.[Summary for patients in Ann Intern Med. 2009 Jul 7; 151(1): I28; PMID: 19451555]. Annals of Internal Medicine 151: 1-10, W11-12.
51. Marre M, Lievre M, Chatellier G, Mann JFE, Passa P, et al. (2004) Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).[Erratum appears in BMJ. 2004 Mar 20; 328(7441): 686]. BMJ 328: 495.
52. Marre M, Puig JG, Kokot F, Fernandez M, Jermendy G, et al. (2004) Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. Journal of Hypertension 22: 1613-1622.
53. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, et al. (1996) Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. New England Journal of Medicine 334: 939-945.
54. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, et al. (2009) Renal and retinal effects of enalapril and losartan in type 1 diabetes. New England Journal of Medicine 361: 40-51.
55. Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, et al. (2008) Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 51: 393-398.
56. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, et al. (1995) Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28: 103-117.
57. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, et al. (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878.
58. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358: 2560-2572.
59. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, et al. (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370: 829-840.
60. Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, et al. (2011) Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365: 327-336.
61. Rachmani R, Slavachevski I, Berla M, Frommer-Shapira R, Ravid M, (2005) Teaching and motivating patients to control their risk factors retards progression of cardiovascular as well as microvascular sequelae of Type 2 diabetes mellitus- a randomized prospective 8 years follow-up study. Diabetic Medicine 22: 410-414.
62. Rahman M, Baimbridge C, Davis BR, Barzilay J, Basile JN, et al. (2008) Progression of Kidney Disease in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin Versus Usual Care: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). American Journal of Kidney Diseases 52: 412-424.
63. Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, et al. (2005) Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Archives of Internal Medicine 165: 936-946.
64. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, et al. (2004) Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351: 1941-1951.
65. Ruggenenti P, Fassi A, Ilieva AP, Iliev IP, Chiurchiu C, et al. (2011) Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. Journal of Hypertension 29: 207-216.
66. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, et al. (2005) Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): Multicentre, randomised controlled trial. Lancet 365: 939-946.
67. Stefoni S, Mosconi G, La Manna G, Bonomini V, Mioli V, et al. (1996) Low-dosage ibopamine treatment in progressive renal failure: a long-term multicentre trial. American Journal of Nephrology 16: 489-499.
68. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547-1559.
69. O'Hare P, Bilbous R, Mitchell T, O'Callaghan CJ, Viberti GC, (2000) Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial. Diabetes Care 23: 1823-1829.
70. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, et al. (1999) Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354: 359-364.
71. Appel LJ, Wright JT Jr, Greene T, Agodoa LY, Astor BC, et al. (2010) Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 363: 918-929.
72. de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, et al. (2011) Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 365: 2366-2376.
73. Dalrymple LS, Katz R, Kestenbaum B, Shlipak MG, Sarnak MJ, et al. (2011) Chronic kidney disease and the risk of end-stage renal disease versus death. J Gen Intern Med 26: 379-385.
74. Lau WK, Blute ML, Weaver AL, Torres VE, Zincke H, (2000) Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc 75: 1236-1242.
75. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, et al. (2012) Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367: 2204-2213.
76. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK, (2008) Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358: 2433-2446.
77. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, et al. (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365: 2255-2267.
78. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, et al. (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. New England Journal of Medicine 355: 2071-2084.
79. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, De Zeeuw D, et al. (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine 361: 2019-2032.
80. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, et al. (2012) Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367: 2089-2099.
81. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, et al. (2006) Correction of anemia with epoetin alfa in chronic kidney disease. New England Journal of Medicine 355: 2085-2098.
82. Kabul S, Shepler B, (2012) A review investigating the effect of allopurinol on the progression of kidney disease in hyperuricemic patients with chronic kidney disease. Clin Ther 34: 2293-2296.
83. Roderick P, Willis NS, Blakeley S, Jones C, Tomson C (2007) Correction of chronic metabolic acidosis for chronic kidney disease patients. Cochrane Database Syst Rev: CD001890.
84. Susantitaphong P, Sewaralthahab K, Balk EM, Jaber BL, Madias NE, (2012) Short- and long-term effects of alkali therapy in chronic kidney disease: a systematic review. Am J Nephrol 35: 540-547.
85. Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J,et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 307: 674-684.